ArticleFrontiers in immunology2021

CTNNB1 Alternation Is a Potential Biomarker for Immunotherapy Prognosis in Patients With Hepatocellular Carcinoma.

Lin Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.